Anti-Human APP Reference Antibody (Donanemab, RUO)

Description: Donanemab (BS10333) is a research-grade recombinant antibody targeting AICD-57. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 6.06mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: AICD-57,A4,Beta-CTF,Proteasenexin-II,Gamma-CTF(50),ABPP,S-APP-beta,APP,Abeta40,Abeta42,AID(59),Amyloidintracellulardomain59,AID(57),S-APP-alpha,Gamma-CTF(59),Beta-secretaseC-terminalfragment,Amyloid-betaprecursorprotein,Amyloidprecursorprotein,Beta-APP42,PreA4,Alzheimerdiseaseamyloidprotein,APPI,PN-II,AICD-59,Alpha-secretaseC-terminalfragment,Amyloid-betaA4protein,Amyloidintracellulardomain57,CVAP,Amyloidintracellulardomain50,Beta-APP40,AD1,Cerebralvascularamyloidpeptide,AID(50),Alpha-CTF,Gamma-CTF(57),AICD-50
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: LY3002813,CAS:1931944-80-7
Background: Amyloid-beta precursor protein (APP/Amyloid beta) is a ~86 kDa protein. Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. APP is the therapeutic target of lecanemab (Leqembi).
References:
1. Baumkötter, F. et al. (2014) The Journal of neuroscience : the official journal of the Society for Neuroscience 34, 11159-72. PMID: 25122912
2. Satpute-Krishnan, P. et al. (2006) Proceedings of the National Academy of Sciences of the United States of America 103, 16532-7. PMID: 17062754
3. Seamster, PE. et al. (2012) Physical biology 9, 055005. PMID: 23011729
Note: For research use only. Not suitable for clinical or therapeutic use.